Cannabinoids Market Size, Growth Rate and Forecast to 2034: Segments, Regions and Key Drivers

The cannabinoids market was worth USD 36 billion in 2025. The forecast runs from 2026 to 2034 and ends at USD 113.6 billion, a CAGR of 13.59%. The study covers five regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Historical data spans 2020 to 2024.

The record before the forecast sets the context. Revenue stood at USD 17 billion in 2020 and USD 31.8 billion in 2024, a compound rate of 16.19% across that period. The forecast rate is lower than the historical one, yet it still holds above 13%. The study reads the direction as settled. What remains open is the mix, and the segment and regional sections below deal with it.

Growth is not spread evenly across the cannabinoid type axis. Cannabigerol (CBG) grows at 22.97% against 13.59% for the market. Its revenue rises from USD 1.44 billion in 2025 to USD 9.66 billion in 2034, and its share of revenue moves from 4% to 8.5%.

The study treats this line as the one that pulls the market average up. At the other end of the axis, a line grows at 11.33%. Whether the market's 13.59% holds depends on how far the faster lines keep their pace. For a producer or investor, position on the cannabinoid type axis is a growth decision as much as a product one.

Geography is the second driver. North America is the largest region at USD 14.4 billion in 2025, or 40% of global revenue. It reaches USD 38.62 billion by 2034 while holding 34% of revenue. Europe is next with 25% of revenue, USD 9 billion in 2025 and USD 27.26 billion in 2034. A regional plan that gives all five regions equal weight misreads where the revenue sits and where it is added.

The segmentation gives a sense of how many separate markets sit inside the total. The study splits it by cannabinoid type, source, product form, extraction method, application, spectrum profile, purity grade, route of administration, distribution channel and legal status. Source alone separates hemp-derived, marijuana-derived, synthetic and semi-synthetic (converted) material. Extraction method runs from CO2 and solvent extraction to solventless extraction, chemical synthesis and biosynthesis. Readers interested in the biological production route can look at the continuous bioprocessing market, which sizes bioreactors, filtration and chromatography systems for biologics manufacturing.

The study's downside path is built on three assumptions: restrictive hemp rules, persistent biomass oversupply and slow clinical adoption. Together they cut volumes and push realised prices lower. In that case the market ends 2034 at USD 82.6 billion, against USD 113.6 billion in the base case. The base year is the same USD 36 billion, and only the forecast period is slower.

The clinical adoption assumption deserves a closer look, because the application axis includes pharmaceuticals alongside nutraceuticals, food and beverages, cosmetics, recreational use and pet products. Prescription (approved drugs) is one of four legal status lines, next to medical cannabis programmes, adult-use regulated products and hemp-derived consumer wellness. Anyone following how trials are supplied and run can read the clinical trial supplies market for that side of the pharmaceutical chain.

Concentration is a second restraint. Cannabidiol (CBD) is the largest line, with 55% of 2025 revenue (USD 19.8 billion). It grows at 11.33% against the market's 13.59%. Revenue still reaches USD 52.26 billion by 2034, though its share falls to 46%. That is a drag on the average and not a decline. A market that leans this heavily on one cannabinoid type line concentrates its exposure there, and a shift in demand for CBD moves the total more than any other single change on the axis.

Country risk adds to the picture. Of North America's USD 14.4 billion in 2025, USD 12.6 billion is the United States, or 87.5% of the region. That figure reaches USD 33.5 billion in 2034. Regional risk in the leading region is, in practice, risk in one country.

**By region.** The shares of 2025 revenue are North America 40%, Europe 25%, Asia Pacific 20%, Latin America 8%, and the Middle East and Africa 7%. North America and Europe hold the largest positions and the study places most of the added revenue there. Asia Pacific is the third region by size and the one a planner would watch next. Latin America and the Middle East and Africa are the smallest.

**By cannabinoid type.** The shares of 2025 revenue are:

• Cannabidiol (CBD): 55%
• Tetrahydrocannabinol (THC): 27%
• Cannabigerol (CBG): 4%
• Cannabinol (CBN): 3%
• Cannabichromene (CBC): 2%
• Cannabidiolic Acid (CBDA): 1%
• Other Cannabinoids: 8%

CBD and THC are the two large lines. CBG is small today but is the line where share changes hands at scale, moving from USD 1.44 billion to USD 9.66 billion. That makes it the place where an entrant can take position without displacing the incumbent in CBD.

**The upside case.** The study also sets out a case in which approval of cannabinoid medicines comes faster, US federal and EU rules for hemp-derived products become more permissive, and reimbursement widens. Volumes rise while prices hold. That case reaches USD 132 billion in 2034, against USD 113.6 billion in the base case. The bear case at USD 82.6 billion and the upside at USD 132 billion bracket the base forecast, and each is worth testing against a reader's own read of regulation and adoption.

For the full segment tables, regional breakdowns and company coverage, see the cannabinoids market report page.